Fundraising FoxIsrael Biotech Fund — 2015 Investments
3 investments dated 2015 · listed companies and verified rows first · show all
Champions Oncology offers a KRAS-focused preclinical platform built on patient-derived xenograft (PDX) models screened with the pan-RAS(ON) inhibitor daraxonrasib, combining in vivo pharmacology with multi-omic characterization to study drug response and resistance.
AI & Machine LearningBiotechHealthtechHackensack, US
Ronnie Morris(Executive Officer, Director)inJames McGorry(Executive Officer)David Miller(Chief Financial Officer)inJoel Ackerman(Executive Officer, Director)inRob Brainin(Chief Executive Officer)inMaria Mancini(Chief Operating Officer)in
Board seatDavid Sidransky· per SEC Form D · $14M raise · filed Mar 2015
Co-investorsBattery VenturesNew Enterprise Associates (NEA)
Orgenesis provides decentralized manufacturing infrastructure for cell and gene therapies, enabling on-site processing of CGTs in regional centers through its POCare™ platform and OMPUL™ mobile processing units.
Advanced ManufacturingBiotechHealthtechMedical DevicesGermantown, US
Neil Reithinger(Executive Officer)inVered Caplan(Executive Officer, Director)inFerber Ferber(Executive Officer)Joseph Tenne(Executive Officer)inSarah Ferber(Executive Officer)
Board seatDavid Sidransky· per SEC Form D · $10M raise · filed Dec 2015
Co-investorsBoundary Holding
BiotechSan Diego, US
Jamie Sulley(Executive Officer, Director)Joanne Barsa(Executive Officer)
BoardFred Knoll(Director)David Sidrandky(Director)Patrick Ostronick(Director)
Board seatDavid Sidransky· per SEC Form D · $800K raise · filed Sep 2015
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.